TXMD Swings to Profit Amid Royalty Model Shift, Mayne Lawsuit Looms

Ticker: TXMD · Form: 10-Q · Filed: Nov 12, 2025 · CIK: 25743

Sentiment: mixed

Topics: Pharmaceutical Royalties, Biotech, Litigation Risk, Going Concern, Women's Health, Licensing Agreements, Financial Turnaround

Related Tickers: TXMD, MYX.AX

TL;DR

TXMD's royalty model is finally paying off with a net profit, but the Mayne Pharma lawsuit is a ticking time bomb that could derail everything.

AI Summary

TherapeuticsMD, Inc. (TXMD) reported a net income of $152 thousand for the three months ended September 30, 2025, a significant improvement from a net loss of $609 thousand in the same period of 2024. For the nine months ended September 30, 2025, the company posted a net income of $50 thousand, reversing a net loss of $2.433 million in the prior year. This turnaround was primarily driven by a substantial increase in license revenue, which grew to $784 thousand for the quarter and $2.129 million for the nine months, up from $547 thousand and $1.094 million respectively in 2024. General and administrative expenses decreased to $1.518 million for the quarter from $1.585 million, and total operating expenses fell to $1.646 million from $1.681 million. Cash and cash equivalents increased to $7.115 million as of September 30, 2025, from $5.059 million at December 31, 2024. The company's strategic shift to a pharmaceutical royalty model in December 2022, following the Mayne Transaction, is central to its current operations, with royalties from IMVEXXY, BIJUVA, and prenatal vitamin products being the primary revenue source. However, ongoing litigation with Mayne Pharma regarding net working capital allowances and indemnification demands poses a significant risk, raising substantial doubt about the company's ability to continue as a going concern.

Why It Matters

This filing reveals TherapeuticsMD's successful pivot to a royalty-based business model, evidenced by its return to profitability. For investors, the positive net income and increased cash position are encouraging signs of stabilization, but the ongoing legal battle with Mayne Pharma introduces considerable uncertainty and could materially impact future financial health. Employees might face instability if the litigation outcome is unfavorable, potentially affecting job security. Customers of products like IMVEXXY and BIJUVA are indirectly affected by the stability of the licensing agreements, which could influence product availability or support. In the competitive pharmaceutical royalty space, TXMD's ability to navigate this legal challenge will be a key determinant of its long-term viability and competitive standing.

Risk Assessment

Risk Level: high — The filing explicitly states, "The potential impact of these factors in conjunction with the uncertainty of the capital markets raises substantial doubt about our ability to continue as a going concern for the next twelve months from the issuance of these financial statements." This is primarily due to the ongoing Mayne Lawsuits, where the company cannot reasonably estimate a range of loss, and the risk that Mayne Pharma's sales of Licensed Products grow more slowly than expected.

Analyst Insight

Investors should exercise extreme caution and consider the high-risk nature of TXMD due to the ongoing litigation with Mayne Pharma and the explicit 'going concern' warning. Await further clarity on the Mayne Lawsuits before making any significant investment decisions, as the outcome could severely impact the company's financial stability and stock value.

Financial Highlights

debt To Equity
0.41
revenue
$784 thousand
operating Margin
-109.2%
total Assets
$38.671 million
total Debt
$11.227 million
net Income
$152 thousand
eps
$0.00
gross Margin
N/A
cash Position
$7.115 million
revenue Growth
+43.3%

Revenue Breakdown

SegmentRevenueGrowth
License Revenue$784 thousand+43.3%
Sublease Income$534 thousand+94.2%
Miscellaneous Income$381 thousand+29.2%

Key Numbers

Key Players & Entities

FAQ

What is TherapeuticsMD's primary source of revenue after the Mayne Transaction?

Following the December 2022 Mayne Transaction, TherapeuticsMD's primary source of revenue is from royalties on products like IMVEXXY, BIJUVA, and prescription prenatal vitamins licensed to pharmaceutical organizations such as Mayne Pharma, Knight Therapeutics, and Theramex.

How did TherapeuticsMD's net income change in the third quarter of 2025 compared to 2024?

TherapeuticsMD reported a net income of $152 thousand for the three months ended September 30, 2025, a significant improvement from a net loss of $609 thousand in the same period of 2024.

What is the nature of the litigation between TherapeuticsMD and Mayne Pharma?

TherapeuticsMD filed a lawsuit against Mayne Pharma on April 8, 2025, for breach of contract, fraudulent inducement, and unjust enrichment related to net working capital allowances. Mayne Pharma filed a countersuit on May 30, 2025, for breach of contract and fraudulent inducement related to the Transaction Agreement.

What is the 'going concern' warning mentioned in TherapeuticsMD's 10-Q filing?

The 'going concern' warning indicates substantial doubt about TherapeuticsMD's ability to continue operations for the next twelve months. This is primarily due to the uncertainty surrounding the Mayne Lawsuits, potential slower-than-expected sales of Licensed Products by Mayne Pharma, and the need for future financings.

What products are covered under the Mayne License Agreement?

The Mayne License Agreement covers IMVEXXY, BIJUVA, prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands, and ANNOVERA, collectively referred to as the 'Products'.

What are the key terms of the royalty payments from Mayne Pharma to TherapeuticsMD?

Mayne Pharma pays TherapeuticsMD royalties at a rate of 8.0% on the first $80.0 million in annual net sales and 7.5% on annual net sales above $80.0 million, subject to adjustments. There are also minimum annual royalties of $3.0 million per year for 12 years, adjusted for inflation.

How much cash and cash equivalents did TherapeuticsMD have as of September 30, 2025?

As of September 30, 2025, TherapeuticsMD had $7.115 million in cash and cash equivalents, an increase from $5.059 million at December 31, 2024.

What was the total consideration TherapeuticsMD received from Mayne Pharma in the 2022 transaction?

The total consideration included a cash payment of $140.0 million at closing, approximately $12.1 million for net working capital, approximately $1.0 million for prepaid royalties, and the right to receive contingent milestone payments and ongoing royalties.

Has TherapeuticsMD raised additional capital recently through equity financing?

In 2023, TherapeuticsMD issued and sold 312,525 shares of Common Stock to Rubric Capital Management LP for $1.15 million and an additional 877,192 shares for $2.0 million. There were no drawdowns in the first nine months of 2025 and 2024.

What is the current status of the net working capital allowance dispute with Mayne Pharma?

Mayne Pharma's calculation of net working capital allowances for payer rebates, wholesale distributor fees, and returns differs significantly from TherapeuticsMD's estimates. TherapeuticsMD has not accrued additional liability as of September 30, 2025, believing the outcome is uncertain and intertwined with the Mayne Lawsuits.

Risk Factors

Industry Context

The pharmaceutical industry, particularly in the women's health sector where TherapeuticsMD operates, is characterized by high R&D costs, stringent regulatory oversight, and intense competition. Companies often rely on strategic partnerships and licensing agreements to monetize intellectual property and manage product lifecycles. The shift towards royalty-based revenue models is a growing trend, allowing companies to generate income from established products without direct operational involvement.

Regulatory Implications

TherapeuticsMD operates within a highly regulated pharmaceutical market. While the current 10-Q does not detail specific new regulatory actions, the company must adhere to FDA regulations for its products and any future product development. The ongoing litigation with Mayne Pharma could also have indirect regulatory implications if it impacts the company's ability to maintain product supply or compliance.

What Investors Should Do

  1. Monitor Litigation Outcome
  2. Analyze Royalty Revenue Sustainability
  3. Evaluate Going Concern Risk

Key Dates

Glossary

Accumulated Deficit
The total cumulative net losses of a company that have not been offset by net income. (TherapeuticsMD has a substantial accumulated deficit of $951.772 million as of September 30, 2025, highlighting its history of losses and raising going concern issues.)
License Revenue
Revenue generated from granting licenses to use intellectual property, such as patents or trademarks. (This is the primary revenue driver for TherapeuticsMD, showing significant growth and indicating the success of its royalty model.)
Going Concern
The assumption that a company will continue to operate for the foreseeable future. (The company's financial situation and ongoing litigation raise substantial doubt about its ability to continue as a going concern, a critical factor for investors and creditors.)
Mayne Transaction
A strategic transaction involving Mayne Pharma that shifted TherapeuticsMD's business model to a pharmaceutical royalty structure. (This transaction is central to the company's current revenue generation and also the source of significant legal disputes.)
Royalty Receivable
Money owed to the company for royalties earned from licensing agreements. (This represents future income streams from licensed products and is a key component of the company's assets.)

Year-Over-Year Comparison

TherapeuticsMD has shown a significant turnaround in profitability, moving from a net loss of $609 thousand in Q3 2024 to a net income of $152 thousand in Q3 2025, and from a nine-month loss of $2.433 million to a $50 thousand income. This improvement is primarily driven by a substantial increase in license revenue, which grew by over 43% for the quarter. Operating expenses have seen a slight decrease, contributing to the improved net income. However, the company's accumulated deficit remains substantial at $951.772 million, and the ongoing litigation with Mayne Pharma introduces significant legal and financial risks not present or as prominent in the prior year's filings.

Filing Stats: 4,570 words · 18 min read · ~15 pages · Grade level 14.8 · Accepted 2025-11-12 17:27:20

Key Financial Figures

Filing Documents

- Financial Information

Part I - Financial Information Item 1.

Financial statements (unaudited)

Financial statements (unaudited) 1 Condensed Consolidated Balance Sheets 1 Condensed Consolidated Statements of Operations 2 Condensed Consolidated Statements of Stockholders' Equity 3 Condensed Consolidated Statements of Cash Flows 4 Notes to Unaudited Condensed Consolidated Financial Statements 5 Item 2.

Management's discussion and analysis of financial condition and results of operations

Management's discussion and analysis of financial condition and results of operations 19 Item 3.

Quantitative and qualitative disclosures about market risk

Quantitative and qualitative disclosures about market risk 29 Item 4.

Controls and procedures

Controls and procedures 29

- Other Information

Part II - Other Information Item 1.

Legal proceedings

Legal proceedings 30 Item 1A.

Risk factors

Risk factors 30 Item 2. Unregistered sales of equity securities and use of proceeds 30 Item 3. Defaults upon senior securities 30 Item 4. Mine safety disclosures 30 Item 5. Other information 31 Item 6. Exhibits 31

- Financial Information

Part I - Financial Information

Financial statements

Item 1. Financial statements TherapeuticsMD, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (in thousands, except per share data) September 30, 2025 December 31, 2024 (Unaudited) Assets: Current assets: Cash and cash equivalents $ 7,115 $ 5,059 Royalty receivable, current portion 3,665 3,562 Prepaid and other current assets 3,723 3,638 Total current assets 14,503 12,259 License rights and other intangible assets, net 3,914 4,321 Right of use assets 5,515 6,102 Royalty receivable, long term 14,269 16,010 Other non-current assets 470 130 Total assets $ 38,671 $ 38,822 Liabilities and stockholders' equity: Current liabilities: Accounts payable $ 263 $ 258 Accrued expenses and other current liabilities 2,015 2,127 Current liabilities of discontinued operations 2,667 2,781 Total current liabilities 4,945 5,166 Operating lease liabilities 5,411 5,542 Other non-current liabilities 871 744 Total liabilities 11,227 11,452 Commitments and contingencies (Note 6) Stockholders' equity: Common stock, par value $ 0.001 ; 32,000 shares authorized, 11,574 and 11,532 issued and outstanding as of September 30, 2025 and December 31, 2024 11 11 Additional paid-in capital 979,205 979,181 Accumulated deficit ( 951,772 ) ( 951,822 ) Total stockholders' equity 27,444 27,370 Total liabilities and stockholders' equity $ 38,671 $ 38,822 The accompanying notes are an integral part of these condensed consolidated financial statements. 1 TherapeuticsMD, Inc. and Subsidiaries Condensed Consolidated Statements of Operations (Unaudited - in thousands, except per share data) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Revenue, net: License revenue $ 784 $ 547 $ 2,129 $ 1,094 Operating expenses: General and administrative 1,518 1,585 4,560 4,884 Impairment of long-lived assets (Note 4) — — — 1,261 Write-

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing